Please use this identifier to cite or link to this item: https://scholarbank.nus.edu.sg/handle/10635/162008
Title: CALPROTECTIN EARLY RHEUMATOID ARTHRITIS ASSOCIATION WITH DISEASE ACTIVITY AND CLINICAL REMISSION
Authors: MANJARI LAHIRI 
Zou, Yuhan
Teoh, Lay Kheng
Cheung, Peter
ANSELM MAK 
KOW NIEN YEE 
Dharmadhikari, Bhushan
Issue Date: 27-Jun-2019
Citation: MANJARI LAHIRI, Zou, Yuhan, Teoh, Lay Kheng, Cheung, Peter, ANSELM MAK, KOW NIEN YEE, Dharmadhikari, Bhushan (2019-06-27). CALPROTECTIN EARLY RHEUMATOID ARTHRITIS ASSOCIATION WITH DISEASE ACTIVITY AND CLINICAL REMISSION. EULAR 78 : 1438-1440. ScholarBank@NUS Repository.
Abstract: Background: Although remission is the goal of treatment in early rheumatoid arthritis (ERA), there is a lack of a sensitive biomarker for evaluating stringent clinical remission. Calprotectin is a potential biomarker for this purpose as it plays a critical role in synovial inflammation, cartilage destruction and bone resorption and its levels are reflective of local joint inflammation.1,2 Objectives: The study compares calprotectin with acute phase reactants such as erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) in discriminating stringent clinical remission from low disease activity (LDA) to moderate disease activity (MDA) in patients with ERA. Methods: A cross-sectional study was conducted on ERA patients from the Singapore Early Arthritis Cohort study. Serum calprotectin, ESR and CRP levels were measured. Receiver operating characteristics curves were used to compare the biomarkers in determining remission according to the Disease Activity Score in 28 Joints with ESR and CRP (DAS28ESR and DAS28CRP), Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI). Results: Eighty ERA patients were included: 72.5% female, 61.3% Chinese, 66.3% seropositive, mean (S.D.) age 54.1 (12.2) and disease duration 2.3 (0.9) years. Calprotectin was significantly correlated with the DAS28ESR (rs=0.509, P-value<0.001), DAS28CRP (rs=0.486, Pvalue<0.001), CDAI (rs=0.487, P-value=0.021) and SDAI (rs=0.567, Pvalue=0.002). Calprotectin had the highest area under the curve (AUC) for discriminating remission based on the DAS28ESR (AUC=0.782, 95% CI 0.659 to 0.868), CDAI (AUC=0.753, 95% CI 0.627 to 0.855) and SDAI (AUC=0.829, 95% CI 0.693 to 0.937). A calprotectin cut-off of 98.9 ng/ml determined remission by the CDAI (sensitivity 0.82, specificity 0.53, 80.0% correctly classified) and a cut-off of 89.4 ng/ml determined remission by the SDAI (sensitivity 0.90, specificity 0.68, 87.5% correctly classified). 96.3% of patients were treated with conventional synthetic diseasemodifying antirheumatic drugs (csDMARDs). Conclusion: Calprotectin is a sensitive biomarker for evaluating stringent clinical remission and can potentially be integrated into treat-to-target algorithms to guide management in ERA patients with apparently quiescent disease activity.
Source Title: EULAR
URI: https://scholarbank.nus.edu.sg/handle/10635/162008
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Calprotectin_published_abstract_Yuhan.pdfPublished version415.77 kBAdobe PDF

OPEN

NoneView/Download

Page view(s)

136
checked on Feb 26, 2021

Download(s)

3
checked on Feb 26, 2021

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.